Low-frequency and high-intensity ultrasonic may play a better role in Ultrasound Contrast Agent drug delivery system in vivo

Sonophoresis temporarily increases skin permeability such that medicine can be delivered transdermally. Cavitation is believed to be the predominant mechanism in sonophoresis. In this study, an ultrasound contrast agent (UCA) strategy was adopted instead of low frequency ultrasound to assure that cavitation occurred, and the efficacy of sonophoresis with UCA was quantitatively analyzed by optical measurements. The target drug used in this study was 0.1 % Definity® in 70% glycerol, which was delivered into porcine skin samples. Glycerol was used because it is an optical clearing agent, and the efficiency of glycerol delivery could be analyzed with optical measurements. The applied acoustic pressure was approximately 600 kPa at 1 MHz ultrasound with a 10% duty cycle for 60 minutes. Experimental results indicated that the measured relative contrast (RC) after sonophoresis with UCA was approximately 80% higher than RC after sonophoresis without UCA. In addition, the variance of RC was also reduced by more than 50% with the addition of a UCA. The use of a UCA appeared to increase cavitation, demonstrating that the use of a UCA can be effective in transdermal drug delivery (TDD).

Download Full-text

Captopril-Loaded Superparamagnetic Nanoparticles as a New Dual-Mode Contrast Agent for Simultaneous In Vitro/In Vivo MR Imaging and Drug Delivery System

Pharmaceutical Chemistry Journal ◽

10.1007/s11094-018-1704-x ◽

2018 ◽

Vol 51 (10) ◽

pp. 852-862 ◽

Cited By ~ 1

Author(s):

Sajjad Abbasi Pour ◽

Hamid Reza Shaterian

Keyword(s):

Drug Delivery ◽

Mr Imaging ◽

Contrast Agent ◽

Drug Delivery System ◽

Delivery System ◽

Superparamagnetic Nanoparticles ◽

Dual Mode

Download Full-text

Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system

Journal of Materials Science Materials in Medicine ◽

10.1007/s10856-017-5900-0 ◽

2017 ◽

Vol 28 (6) ◽

Cited By ~ 2

Author(s):

Sajjad Abbasi Pour ◽

Hamid Reza Shaterian

Keyword(s):

Drug Delivery ◽

Contrast Agent ◽

Drug Delivery System ◽

Delivery System ◽

Superparamagnetic Nanoparticles ◽

Mri Imaging

Download Full-text

Glucan particles as anti-inflammatory agent and drug delivery system for natural compounds in experimentally induced intestinal inflammation in vivo

10.1055/s-0037-1608375 ◽

2017 ◽

Author(s):

D Rotrekl ◽

Z Vochyánová ◽

L Paráková ◽

I Saloň ◽

P Šalamúnová ◽

...

Keyword(s):

Drug Delivery ◽

Drug Delivery System ◽

Delivery System ◽

Intestinal Inflammation ◽

Natural Compounds ◽

Inflammatory Agent ◽

Anti Inflammatory ◽

Experimentally Induced

Download Full-text

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

International Journal of Drug Delivery Technology ◽

10.25258/ijddt.v7i04.10647 ◽

2017 ◽

Vol 7 (04) ◽

Author(s):

ShirishaG. Suddala ◽

S. K. Sahoo ◽

M. R. Yamsani

Keyword(s):

Rheumatoid Arthritis ◽

Drug Delivery ◽

Drug Release ◽

Drug Delivery System ◽

Delivery System ◽

Lag Time ◽

Oral Dosage ◽

Lag Phase ◽

Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

Download Full-text